AbbVie is strutting into 2025 like it owns the lab, thanks to a performance cocktail of smart acquisitions, clinical wins, ...

Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics ...

AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...

AbbVie’s stock faced a chilly reception on May 6, plunging 4.55% and ending the day at $187.15. Despite strong fundamentals ...

After a two-year surge of 53%, the stock market has been taken for a wild ride in 2025, driven by uncertainties surrounding ...

After a two-year surge of 53%, the stock market has been taken for a wild ride in 2025, driven by uncertainties surrounding ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

WisdomTree US High Dividend ETF (DHS) focuses on high-yield, quality U.S. equities, favoring defensive sectors. Read an ...

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.

Ironwood Pharmaceuticals, Inc.’s IRWD share price has surged by 5.57%, which has investors questioning if this is right time ...